Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-07-2020 | NSCLC | Original Article – Clinical Oncology

Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data

Authors: Huijuan Chen, Aiqin Wang, Jing Wang, Zeming He, Yanqiu Mao, Liming Liu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2020

Abstract

Purpose

Approximately 30% of NSCLC patients cannot obtain tissue sample or sufficient tissue sample for molecular subtyping. Cell-free circulating tumor DNA (ctDNA) in plasma is a potential alternative specimen type to assess genomic variants in patients with non-small cell lung cancer (NSCLC). The purpose of this study was to identify the genomic alteration profile of ctDNA in real-world Chinese NSCLC patients.

Methods

A total of 325 subjects with pathological diagnosis of NSCLC were enrolled. 10 ml Peripheral blood was collected in streck tube, and ctDNA NGS analysis was carried out using an Ampliseq-based 11-gene panel.

Results

295 out of 325 patients (90.8%) had detected ctDNA results. In 62.1% (183/295) of these cases, at least one genomic alterations was detected. Frequency altered genes were EGFR (27.8%), TP53 (22.7%), KRAS (21.36%), and PIK3CA (4.75%). EGFR mutation was associated with female, younger age (< 65 years), and adenocarcinoma. The most common mutations in EGFR were L858R (39.4%), exon19 deletions (31.73%), and T790M (18.3%); G13S was the most common alterations in KRAS. TP53 mutation was most occurred in exon7 and exon8. TP53 mutation was significantly more common in patients with history of radiochemotherapy/chemotherapy therapy, and T790M was mainly found in patients with TKIs treatments. Co-existence EGFR mutation with KRAS and different multiple gene co-mutation panels were detected.

Conclusion

In Chinese NSCLC patients, EGFR mutation was significantly associated with female, younger age (< 65 years), and adenocarcinoma. Genomic profiles of NSCLC were associated with the treatment history; TP53 mutation was significantly more frequent in the patients with history of radiochemotherapy/chemotherapy therapy. Various multiple genes co-mutation panels, especially EGFR and KRAS co-mutation, were observed in the ctDNA of Chinese NSCLC patients.

Alì G, Proietti A, Pelliccioni S et al (2014) ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med 138(11):1449–1458PubMedCrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef

Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543–550CrossRef

Coombs CC, Zehir A, Devlin SM et al (2017) Therapy-related clonal therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21(3):374–382.e4PubMedPubMedCentralCrossRef

Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954PubMedCrossRef

Del Re M, Tiseo M, Bordi P et al (2017) Contribution of KRAS mutations and c.2369 C%3eT(p.T790M)EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget 8(8):13611–13619PubMedCrossRef

Denis MG, Lafourcade MP, Le Garff G et al (2019) Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. J Thorac Dis 11(4):1370–1378PubMedPubMedCentralCrossRef

Drilon A, Wang L, Arcila ME et al (2015) Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 21(16):3631–3639PubMedPubMedCentralCrossRef

Ettinger DS, Wood DE, Akerley W et al (2015) Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw 13(5):515–524PubMedCrossRef

Finlay MR, Anderton M, Ashton S et al (2014) Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 57(20):8249–8267PubMedCrossRef

Gainor JF, Shaw AT (2013) Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31(31):3987–3996PubMedPubMedCentralCrossRef

Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892PubMedPubMedCentralCrossRef

Hirsch FR, Bunn PA Jr (2009) EGFR testing in lung cancer is ready for prime time. Lancet Oncol 10(5):432–433PubMedCrossRef

Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488–2498PubMedPubMedCentralCrossRef

Jia N, Sun Z, Gao X, Cheng Y et al (2019) Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response. Front Genet 10:470. https://doi.org/10.3389/fgene.2019.00470.eCollection CrossRefPubMedPubMedCentral

JiangY QY, Minn AJ, Zhang NR (2016) Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proc Natl Acad Sci USA 113(37):E5528–E5537CrossRef

Katayama R, Friboulet L, Koike S et al (2014) Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib. Clin Cancer Res 20(22):5686–5696PubMedPubMedCentralCrossRef

Kato S, Schwaederlé MC, Fanta PT et al (2019) Genomic assessment of blood-derived circulating tumor DNA in patients with colorectal cancers: correlation with tissue sequencing, therapeutic response, and survival. JCO Precis Oncol. https://doi.org/10.1200/PO.18.00158 CrossRefPubMedPubMedCentral

Kosaka T, Yamaki E, Mogi A, Kuwano H (2011) Mechanisms of resistance to EGFR TKIs and development of a new generations of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011:165214. https://doi.org/10.1155/2011/165214 CrossRefPubMedPubMedCentral

Lebofsky R, Decraene C, Bernard V et al (2015) Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumorgenotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 9(4):783–790PubMedCrossRef

Lee TH, Montalvo L, Chrebtow V, Busch MP (2001) Quantitation of genomic DNA in plasma and serum samples:higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41(2):276–282PubMedCrossRef

Li S, Li L, Zhu Y, Huang C et al (2014) Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer 110(11):2812–2820PubMedPubMedCentralCrossRef

Medina Diaz I, Nocon A, Mehert DH, Fredebohm J, Diehl F, Holtrup F (2016) Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS ONE 11(11):e0166354PubMedPubMedCentralCrossRef

Minari R, Bordi P, Del Re M et al (2018) Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer 115:21–27PubMedCrossRef

Nguyen KS, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281–289PubMedPubMedCentralCrossRef

Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M (2017) Guide to detecting epidermal growth factor receptor(EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget 8(7):12501–12516PubMedCrossRef

Ohashi K, Sequist LV, Arcila ME et al (2012) Lung cancers with acquired resistance to EGFR resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 109(31):E2127–E2133PubMedCrossRefPubMedCentral

Page K, Powles T, Slade MJ, De Bella MT, Walker RA, Coombes RC, Shaw JA (2006) The importance of careful blood processing in isolation of cell-free DNA. Ann NY Acad Sci 1075:313–317PubMedCrossRef

Peled N, Roisman LC, Miron B et al (2017) Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer. J Thorac Oncol 12(7):e81–e84PubMedCrossRef

Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAF( V600E) mutant metastatic non-small cell lung cancer: an open label, multicenter phase 2 trial. Lancet Oncol 17(7):984–993PubMedPubMedCentralCrossRef

Planchard D, Smit EF, Groen HJM et al (2017) Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 18(10):1307–1316CrossRefPubMed

Que D, Xiao H, Zhao B et al (2016) EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer Biol Ther 17(3):320–327PubMedPubMedCentralCrossRef

Rajagopalan H, Bardelli A, Lengauer C et al (2002) Tumorigenesis:RAF/RAS oncogenes and mismatch -repair status. Nature 418(6901):934PubMedCrossRef

Rolfo C, Mack PC, Scagliotti GV et al (2018) Liquid biopsy for advanced non-small cell lung cancer( NSCLC): a statement paper from the IASLC. J Thorac Oncol 13(9):1248–1268PubMedCrossRef

Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967PubMedCrossRef

Rosell R, Molina MA, Costa C et al (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17(5):1160–1168PubMedCrossRef

Schrock AB, Welsh A, Chung JH et al (2019) Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced Non-Small Cell Lung Cancer. J Thorac Oncol 14(2):255–264PubMedCrossRef

Schwaederlé MC, Patel SP, Husain H et al (2017) Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res 23(17):5101–5111PubMedPubMedCentralCrossRef

Shepherd FA, Domerg C, Hainaut P et al (2013) Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small- cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 31(17):2173–2181PubMedPubMedCentralCrossRef

Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M, Kohlmann A (2016) Optimised pre-ana lytica methods improve KRAS mutation detection in circulating TumourDNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS ONE 11(2):e0150197PubMedPubMedCentralCrossRef

Sholl LM, Aisner DL, Varella-Garcia M et al (2015) Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol 10(5):768–777PubMedPubMedCentralCrossRef

Sorber L, Zwaenepoel K, De Winne K, Van Casteren K et al (2018) A multicenter study to assess EGFR mutational status in plasma: focus on an optimized workflow for liquid biopsy in a clinical setting. Cancers (Basel) 10(9):E290CrossRef

Sueoka-Aragane N, Katakami N, Satouchi M et al (2016) Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci 107(2):162–167PubMedPubMedCentralCrossRef

Thompson JC, Yee SS, Troxel AB et al (2016) Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22(23):5772–5782PubMedPubMedCentralCrossRef

Tokumo M, Toyooka S, Kiura K et al (2005) The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11(3):1167–1173PubMed

Torquato S, Pallavajjala A, Goldstein A et al (2019) Genetic alterations detected in cell- free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer. JCO Precis Oncol. https://doi.org/10.1200/PO.18.00227 CrossRefPubMedPubMedCentral

Weber B, Hager H, Sorensen BS et al (2014) EGFR mutation frequency and effectiveness of erlotinib:a prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer 83(2):224–230PubMedCrossRef

Yang JC, Hirsh V, Schuler M et al (2013) Symptom control and quality of life in LUX-lung 3: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutation. J Clin Oncol 31(27):3342–3350PubMedCrossRef

Zheng G, Lin MT, Lokhandwala PM et al (2016) Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next generation sequencing. Cancer Cytopathol 124(10):744–753PubMedCrossRef

Zugazagoitia J, Ramos I, Trigo JM et al (2019) Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol 30(2):290–296CrossRefPubMed

Title: Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data
Authors: Huijuan Chen
Aiqin Wang
Jing Wang
Zeming He
Yanqiu Mao
Liming Liu
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
NSCLC
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03192-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2020

Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas

Unilateral versus bilateral lymph-nodal metastases and oncologic outcome in vulvar cancer patients

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis

Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

Protective effect of kava constituents in an in vitro model of oral mucositis

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page